Literature DB >> 17724007

Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas.

Eleni Thodou1, Theodore Argyrakos, George Kontogeorgos.   

Abstract

OBJECTIVE: Galectin-3 (Gal-3) belongs to the family of carbohydrate-binding proteins with high affinity for galactoside and is involved in many biological processes including cell growth and differentiation, cell adhesion, tumor progression, apoptosis and metastasis. The aim of this study was to disclose differences in the expression of Gal-3 in silent and functioning corticotroph pituitary adenomas.
DESIGN: We examined 30 pituitary adenomas (19 functioning corticotroph, 11 silent corticotroph adenomas). Two prolactinomas and 2 functioning somatotroph adenomas served as positive controls. Antigen retrieval was done by three-minute incubation via pressure boiler in citrate buffer solution, pH 6.0. A polymer was used as a secondary link to DAB chromogen. The independent variables t-test was used for comparison of the mean expression of Gal-3 in the two different corticotroph adenoma subgroups.
RESULTS: Eighteen of the functioning corticotroph adenomas (94.73%) were positive for Gal-3 with a cytoplasmic and focally membranous distribution; two cases also exhibited nuclear expression, whereas 9 of the silent corticotroph adenomas (81.81%) had zero or<1% expression of Gal-3 (p=0.001).
CONCLUSIONS: Gal-3 is highly expressed in functioning corticotroph adenomas of the pituitary gland, while silent adenomas exhibit very focal to null expression of Gal-3. This observation can be used in the pathological diagnosis to separate functioning from silent corticotroph adenomas of the pituitary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724007

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  12 in total

Review 1.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

2.  A Postnatal Pax7 Progenitor Gives Rise to Pituitary Adenomas.

Authors:  Tohru Hosoyama; Koichi Nishijo; Melinda M Garcia; Beverly S Schaffer; Sachiko Ohshima-Hosoyama; Suresh I Prajapati; Michael D Davis; Wilmon F Grant; Bernd W Scheithauer; Daniel L Marks; Brian P Rubin; Charles Keller
Journal:  Genes Cancer       Date:  2010-04-01

Review 3.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

4.  Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells.

Authors:  Chui-Xue Huang; Yong-Hong Hou; Yun-Sheng Liu
Journal:  Neurosci Bull       Date:  2008-02       Impact factor: 5.203

Review 5.  Immunohistochemical Biomarkers in Pituitary Pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 6.  In search of a prognostic classification of endocrine pituitary tumors.

Authors:  Jacqueline Trouillas
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 7.  Update on pituitary adenomas in the 2017 World Health Organization classification: innovations and perspectives.

Authors:  George Kontogeorgos
Journal:  Hormones (Athens)       Date:  2021-01-16       Impact factor: 2.885

Review 8.  Clinical and Pathological Aspects of Silent Pituitary Adenomas.

Authors:  Juliana Drummond; Federico Roncaroli; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

Review 9.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 10.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.